Phoenix Wealth Advisors Boosts Stake in Johnson & Johnson (NYSE:JNJ)

Phoenix Wealth Advisors grew its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 1.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 21,032 shares of the company’s stock after buying an additional 373 shares during the quarter. Johnson & Johnson accounts for approximately 1.9% of Phoenix Wealth Advisors’ portfolio, making the stock its 10th biggest position. Phoenix Wealth Advisors’ holdings in Johnson & Johnson were worth $3,276,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in JNJ. Rather & Kittrell Inc. boosted its stake in shares of Johnson & Johnson by 2.0% during the 2nd quarter. Rather & Kittrell Inc. now owns 2,909 shares of the company’s stock valued at $481,000 after purchasing an additional 58 shares in the last quarter. Capital Square LLC boosted its stake in shares of Johnson & Johnson by 1.4% during the 2nd quarter. Capital Square LLC now owns 4,245 shares of the company’s stock valued at $703,000 after purchasing an additional 58 shares in the last quarter. Wagner Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 1.3% during the 2nd quarter. Wagner Wealth Management LLC now owns 4,543 shares of the company’s stock valued at $752,000 after purchasing an additional 59 shares in the last quarter. Chesapeake Wealth Management boosted its stake in shares of Johnson & Johnson by 0.7% during the 2nd quarter. Chesapeake Wealth Management now owns 9,196 shares of the company’s stock valued at $1,522,000 after purchasing an additional 60 shares in the last quarter. Finally, RPG Investment Advisory LLC lifted its position in Johnson & Johnson by 1.2% during the 2nd quarter. RPG Investment Advisory LLC now owns 4,876 shares of the company’s stock valued at $807,000 after acquiring an additional 60 shares during the period. Institutional investors and hedge funds own 68.40% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, November 17th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, January 24th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Finally, Raymond James lifted their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Eight analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $176.14.

Get Our Latest Report on JNJ

Johnson & Johnson Stock Up 1.5 %

Shares of Johnson & Johnson stock opened at $158.07 on Wednesday. The firm’s 50 day moving average price is $158.08 and its 200-day moving average price is $159.05. The company has a market cap of $380.52 billion, a P/E ratio of 11.45, a PEG ratio of 2.63 and a beta of 0.53. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The business had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. During the same period in the previous year, the business posted $2.35 EPS. The business’s quarterly revenue was down 9.7% compared to the same quarter last year. On average, sell-side analysts predict that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be paid a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 3.01%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s dividend payout ratio is currently 34.47%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.